Lonza to Produce Monoclonal Antibodies for Opsona Therapeutics

Lonza says it has entered into an agreement with drug developer Opsona Therapeutics (Dublin) to produce Opsona’s monoclonal antibody OPN-305. The agreement calls for Lonza to provide process development and cGMP manufacturing services for preclinical and Phase 1 studies using Lonza’s GS Gene Expression System. Financial details of the deal were not disclosed. Opsona is focused on novel therapeutic and preventative approaches to autoimmune and inflammatory diseases. OPN-305 is a fully humanized antibody, which has generated positive pre-clinical data...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers